1st Jun 2006 10:46
Cyprotex PLC01 June 2006 Press Release 1 June 2006 CYPROTEX PLC ("Cyprotex" or "the Group") AGM Statement Cyprotex PLC (LSE: CRX), the drug discovery technology and information companyannounces that further to its Annual General Meeting held today at 10.00am atthe Institute of Directors, 116 Pall Mall, London all the resolutions put toshareholders were duly passed. The following statement was made by the CEO,Robert Morrisson Atwater. "The Group has continued to take important strides forward over the past twelvemonths. The major phase of investment has been completed and Cyprotex is nowsetting international standards in high throughput ADMET screening. High levelsof automation and proprietary technologies provide exceptional opportunities forour shareholders, the benefits of which we expect to be realised in the comingyear. "Recent announcements regarding the significant expansion of the Group's seniorsales force in the US and contract successes reflect both the confidence of ourmanagement and our further evolution as a trusted service partner in the worldof international drug discovery. "Additional representation at Board level has been made during the period tofully meet the requirements of a growing and ambitious company in the globalmarketplace. We look forward with confidence to a productive year ahead" The presentation given this morning to shareholders is available on theCompany's website: www.cyprotex.com - Ends - For further information: Cyprotex PLCRobert Morrisson Atwater Tel: +44 (0) 1625 505 100Chairman & Chief Executive [email protected] www.cyprotex.com Code Securities LimitedChris Collins, Corporate Finance Tel: +44 (0) 20 7776 [email protected] www.codesecurities.com Media enquiries: AbchurchHeather Salmond / Georgina Bonham Tel: +44 (0) 20 7398 [email protected] www.abchurch-group.com Notes for Editors: Cyprotex plc - www.cyprotex.com Cyprotex is a specialist provider of experimental and computational capabilitiesto support ADME (Absorption/Distribution/Metabolism/Excretion), toxicity andpharmacokinetics assessment for drug discovery partners. Its core productsinclude the Cloe ScreenTM in vitro ADME/toxicity service, and Cloe PKTM - apharmacokinetics prediction system which integrates core ADME andphysicochemical compound data to predict compound levels in plasma and majororgans in the body. This unique combination of technologies is aimed atimproving pharmaceutical productivity by improving the quality of compoundlibraries and drug candidates progressing through the drug pipeline. Cyprotexis based in the UK and is listed on the London Stock Exchange (CRX). This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
CRX.L